Goldman Sachs
FATE icon

Goldman Sachs’s Fate Therapeutics FATE Stock Holding History

Goldman Sachs’s Portfolio FATE Stock Details FATE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.59M Sell
1,327,757
-107,283
-7% -$131K ﹤0.01% 4732
2025
Q4 		$1.41M Sell
1,435,040
-51,367
-3% -$61.7K ﹤0.01% 4876
2025
Q3 		$1.87M Sell
1,486,407
-1,025,269
-41% -$1.11M ﹤0.01% 4547
2025
Q2 		$2.81M Buy
2,511,676
+52,702
+2% +$61.3K ﹤0.01% 3910
2025
Q1 		$1.94M Sell
2,458,974
-17,440
-0.7% -$21.4K ﹤0.01% 4186
2024
Q4 		$4.09M Sell
2,476,414
-346,989
-12% -$874K ﹤0.01% 3656
2024
Q3 		$9.88M Buy
2,823,403
+474,849
+20% +$1.85M ﹤0.01% 2743
2024
Q2 		$7.7M Buy
2,348,554
+336,296
+17% +$1.47M ﹤0.01% 2759
2024
Q1 		$14.8M Buy
2,012,258
+1,421,265
+240% +$8.8M ﹤0.01% 2109
2023
Q4 		$2.21M Buy
590,993
+96,527
+20% +$228K ﹤0.01% 3840
2023
Q3 		$1.05M Sell
494,466
-590,367
-54% -$1.96M ﹤0.01% 4241
2023
Q2 		$5.16M Sell
1,084,833
-243,828
-18% -$1.35M ﹤0.01% 3084
2023
Q1 		$7.57M Buy
1,328,661
+518,625
+64% +$3.13M ﹤0.01% 2673
2022
Q4 		$8.17M Sell
810,036
-231,691
-22% -$4.35M ﹤0.01% 2758
2022
Q3 		$23.3M Sell
1,041,727
-42,943
-4% -$1.24M 0.01% 1735
2022
Q2 		$26.9M Buy
1,084,670
+858,193
+379% +$23.7M 0.01% 1650
2022
Q1 		$8.78M Sell
226,477
-180,694
-44% -$7M ﹤0.01% 2821
2021
Q4 		$23.8M Sell
407,171
-163,752
-29% -$9.28M ﹤0.01% 1958
2021
Q3 		$33.8M Sell
570,923
-22,519
-4% -$1.77M 0.01% 1591
2021
Q2 		$51.5M Sell
593,442
-226,100
-28% -$18.2M 0.01% 1231
2021
Q1 		$67.6M Buy
819,542
+44,128
+6% +$4.23M 0.02% 926
2020
Q4 		$70.5M Sell
775,414
-533,553
-41% -$33.1M 0.02% 856
2020
Q3 		$52.3M Buy
1,308,967
+265,771
+25% +$9.28M 0.01% 960
2020
Q2 		$35.8M Buy
1,043,196
+298,727
+40% +$8.9M 0.01% 1224
2020
Q1 		$16.5M Buy
744,469
+69,032
+10% +$1.75M 0.01% 1656
2019
Q4 		$13.2M Buy
675,437
+218,850
+48% +$3.48M ﹤0.01% 2221
2019
Q3 		$7.09M Buy
456,587
+12,471
+3% +$239K ﹤0.01% 2593
2019
Q2 		$9.02M Buy
444,116
+65,266
+17% +$1.18M ﹤0.01% 2437
2019
Q1 		$6.66M Buy
378,850
+33,892
+10% +$535K ﹤0.01% 2747
2018
Q4 		$4.43M Buy
344,958
+245,281
+246% +$3.42M ﹤0.01% 2988
2018
Q3 		$1.62M Buy
99,677
+72,379
+265% +$856K ﹤0.01% 3741
2018
Q2 		$310K Buy
+27,298
New +$301K ﹤0.01% 4766
2018
Q1 		– Sell
-50,966
Closed -$311K – 6031
2017
Q4 		$311K Sell
50,966
-75,260
-60% -$336K ﹤0.01% 5158
2017
Q3 		$500K Buy
126,226
+14,451
+13% +$49.1K ﹤0.01% 5086
2017
Q2 		$362K Sell
111,775
-32,278
-22% -$124K ﹤0.01% 5353
2017
Q1 		$655K Buy
144,053
+119,200
+480% +$436K ﹤0.01% 4769
2016
Q4 		$62K Sell
24,853
-10,564
-30% -$28.3K ﹤0.01% 6325
2016
Q3 		$111K Sell
35,417
-549
-2% -$1.33K ﹤0.01% 6181
2016
Q2 		$61K Sell
35,966
-137,958
-79% -$250K ﹤0.01% 6343
2016
Q1 		$313K Buy
173,924
+147,233
+552% +$303K ﹤0.01% 5238
2015
Q4 		$90K Buy
26,691
+11,894
+80% +$50K ﹤0.01% 6237
2015
Q3 		$79K Buy
14,797
+2,547
+21% +$17.4K ﹤0.01% 6606
2015
Q2 		$79K Sell
12,250
-24,763
-67% -$148K ﹤0.01% 6717
2015
Q1 		$181K Sell
37,013
-36,423
-50% -$181K ﹤0.01% 6084
2014
Q4 		$369K Sell
73,436
-10,256
-12% -$45.3K ﹤0.01% 5571
2014
Q3 		$427K Buy
83,692
+15,815
+23% +$91.5K ﹤0.01% 5420
2014
Q2 		$428K Buy
67,877
+41,567
+158% +$293K ﹤0.01% 5462
2014
Q1 		$256K Sell
26,310
-14,681
-36% -$113K ﹤0.01% 5855
2013
Q4 		$257K Buy
+40,991
New +$258K ﹤0.01% 5801

Other funds holding FATE

RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $652M AUM 198.07% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Goldman Sachs's FATE Position: Q1 2026 in Review

Goldman Sachs reduced its Fate Therapeutics (FATE) stake by 7.5% in Q1 2026, selling an estimated $131K and leaving 1,327,757 shares worth $1.59M. The position accounts for ﹤0.01% of the portfolio, ranked #4732.

Goldman Sachs first reported a position in FATE in Q4 2013 and has held it in 49 quarters since. The position peaked at $70.5M in Q4 2020. 157 funds tracked by Wall St. Rank hold FATE as of Q1 2026.

  • Goldman Sachs held 1,327,757 shares of Fate Therapeutics worth $1.59M as of Q1 2026.
  • Goldman Sachs sold 107,283 Fate Therapeutics shares in Q1 2026, an estimated $131K.
  • Fate Therapeutics made up ﹤0.01% of Goldman Sachs's portfolio in Q1 2026, its #4732 holding.
  • Goldman Sachs first reported a position in Fate Therapeutics in Q4 2013 and has held it in 49 quarters since.
  • Goldman Sachs's Fate Therapeutics position peaked at $70.5M in Q4 2020.
  • 157 funds tracked by Wall St. Rank held Fate Therapeutics as of Q1 2026.

Based on Goldman Sachs's 13F filing for Q1 2026, filed 15 May 2026.